Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Abstract Text:

    steven a rosenbergSteven A Rosenberg,james c yangJames C Yang,richard m sherryRichard M Sherry,patrick hwuPatrick Hwu,suzanne l topalianSuzanne L Topalian,douglas j schwartzentruberDouglas J Schwartzentruber,nicholas p restifoNicholas P Restifo,leah r haworthLeah R Haworth,claudia a seippClaudia A Seipp,linda j freezerLinda J Freezer,kathleen e mortonKathleen E Morton,sharon a mavroukakisSharon A Mavroukakis,donald e whiteDonald E White,

    Immunization with plasmid DNA represents a theoretically attractive method for increasing T cell responses against cancer antigens. We administered plasmid DNA encoding the gp100 melanoma-melanocyte differentiation antigen to 22 patients with metastatic melanoma and evaluated immunologic and clinical responses. Patients were randomized to receive plasmid DNA either intradermally (n = 10) or intramuscularly (n = 12). One patient (4.5%) exhibited a partial response of several subcentimeter cutaneous nodules. All other patients had progressive disease. Of 13 patients with cells available before and after immunization, no patient exhibited evidence of the development of anti-gp100 cell responses using in vitro boost assays. The same assays were capable of demonstrating immunologic precursors after immunization with fowl poxvirus encoding gp100 or with gp100 peptides. We were thus unable to demonstrate significant clinical or immunologic responses to plasmid DNA encoding the "self" nonmutated gp100 tumor antigen.

    Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Publishing Authors By Initials

    sa rosenbergSA Rosenberg,jc yangJC Yang,rm sherryRM Sherry,p hwuP Hwu,sl topalianSL Topalian,dj schwartzentruberDJ Schwartzentruber,np restifoNP Restifo,lr haworthLR Haworth,ca seippCA Seipp,lj freezerLJ Freezer,ke mortonKE Morton,sa mavroukakisSA Mavroukakis,de whiteDE White,

    For similar proteins: recombinant proteins: vaccines, synthetic: vaccines, dna research abstracts see: proteins: recombinant proteins: vaccines, synthetic: vaccines, dna research

    PUBMED ID PMID:

    MEDLINE DATE:

    Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Journal Published:

    PUBLICATION TYPE: Randomized Controlled Trial

    Journal: Human gene therapy

    VOLUME: 14

    Page Numbers: 709-14

    Journal Abbreviation: Hum. Gene Ther.

    ISSN: 1043-0342

    DAY: 20

    MONTH: May

    YEAR: 2003

    Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9008950

    Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Keywords Mesh Terms:

    KEYWORDS: Vaccines, DNA

    MESH TERMS: therapeutic use

    Chemical & Substance for Abstract: Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Information

    Substance Name: melanocyte lineage-specific antigen gp10

    Registry Number: 0

    Grant and Affiliation Information for Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

    AFFILIATION: Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1502, USA. sar@nih.gov

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NCI

    GRANT: Z01 BC010763-01

    ACRONYM: BC

    MEDLINETA: Hum Gene Ther

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News